New option listings for April 9th include Alumis Inc (ALMS), LEVERAGE SHARES 2X LONG ASML DAILY ETF (ASMG), Arrivent Biopharma Inc (AVBP), REX BITCOIN CORPORATE TREASURY CONVERTIBLE BOND (BMAX), Benitec Biopharma (BNTC), SIMPLIFY TREASURY OPTION INCOME ETF (BUCK), VANECK CMCI COMMODITY STRATEGY ETF (CMCI), Contineum Therapeutics Inc (CTNM), Deutsche X trackers MSCI Eurozone Hedged Equity ETF (DBEZ), FRANKLIN FTSE INDIA ETF (FLIN), FIRST TRUST IPOX EUROPE EQUITY OPPORTUNITIES ETF (FPXE), Goldman Sachs ActiveBeta Europe Equity ETF (GSEU), Catalyst Biosciences Inc (GYRE), THEMES US INFRASTRUCTURE ETF (HWAY), LENZ Therapeutics (LENZ), LIFE360, INC. (LIF), THEMES LITHIUM & BATTERY METAL MINERS ETF (LIMI), MBX BIOSCIENCES, INC. (MBX), LEVERAGE SHARES 2X LONG NVDA DAILY ETF (NVDG), Sezzle Inc (SEZL), SPROTT SILVER MINERS & PHYSICAL SILVER ETF (SLVR), THEMES US SMALL CAP CASH FLOW CHAMPIONS ETF (SMCF), VANECK FABLESS SEMICONDUCTOR ETF (SMHX), Tectonic Therapeutic Inc (TECX), LEVERAGE SHARES 2X LONG TSLA DAILY ETF (TSLG), and THEMES US R&D CHAMPIONS ETF (USRD).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALMS:
- Alumis Inc. Reports 2024 Results and Strategic Merger
- Strategic Partnerships and Financial Projections Bolster Buy Rating for Alumis Inc.
- Alumis, Kaken Pharmaceutical enter ESK-001 collaboration and licensing agreement
- Positive Buy Rating for Alumis Inc. Driven by Promising TYK2 Inhibitors and Strategic Advancements
- Alumis price target lowered to $15 from $19 at H.C. Wainwright